A trial looking at Xilonix for bowel cancer
Cancer type:
Status:
Phase:
This trial looked at Xilonix for bowel cancer that had grown despite having 
. It was for people whose cancer couldn’t be removed with surgery, or had spread to other parts of the body.
Xilonix is also called bermekimab and MABp1.
The trial was open for people to join in 2014 and 2015. The team published the results in 2017. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Doctors usually use chemotherapy to treat bowel cancer that can’t be removed or has spread. But sometimes this doesn’t work and the cancer continues to grow.
People in this situation can also have problems such as:
- loss of muscle mass (muscle wasting)
- loss of appetite
- tiredness
- pain
Researchers wanted to find ways to reduce these symptoms.
Xilonix (pronounced sil-on-nix) is a type targeted drug called a monoclonal antibody. It can help to stop or slow down cancer growth. Researchers hoped it would help to reduce some of the symptoms listed above.
The people taking part were put into a treatment group at random. For every 3 people who joined the trial:
- 2 people had Xilonix
- 1 person had a dummy drug (placebo)
The main aims of this trial were to find out:
- if Xilonix can help reduce muscle wasting and other symptoms
- if Xilonix can help improve
quality of life - more about the side effects
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
T Hickish and others
The Lancet Oncology, 2017. Volume 18, issue 2, pages 192 - 201.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Tamas Hickish
Supported by
NIHR Clinical Research Network: Cancer
XBiotech GmbH
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
